All data are based on the daily closing price as of April 28, 2025
h
Hugel
145020.KQ
245.95 USD
-4.57
-1.82%
Overview
Last close
245.95 usd
Market cap
2.65B usd
52 week high
251.65 usd
52 week low
110.69 usd
Target price
290.19 usd
Valuation
P/E
N/A
Forward P/E
23.9234
Price/Sales
10.0668
Price/Book Value
4.8198
Enterprise Value
2.42B usd
EV/Revenue
9.3516
EV/EBITDA
19.2321
Key financials
Revenue TTM
258.46M usd
Gross Profit TTM
198.96M usd
EBITDA TTM
125.58M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
637.36M usd
Net debt
N/A usd
About
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.